COVID-19 Vaccines Highly Effective Against B.1.617.2 Variant That Was First Found In India, Says UK Study

COVID-19 Vaccines Highly Effective Against B.1.617.2 Variant That Was First Found In India, Says UK Study

The study by Public Health England shows that vaccine effectiveness against symptomatic disease from the B.1.617.2 variant is similar after two doses compared to the B1.1.7 Variant Of Concern discovered in the UK
This study provides reassurance that two doses of either vaccine offer high levels of protection against symptomatic disease from the B1.617.2 variantThis study provides reassurance that two doses of either vaccine offer high levels of protection against symptomatic disease from the B1.617.2 variant
Highlights
  • AstraZeneca Vaccine is 60% effective against B1.617.2 variant: Study
  • Pfizer vaccine is 88% effective against B1.617.2: Study
  • Infected people with even 1 shot of vaccine don’t need hospitals: Expert

New Delhi: A study by Public Health England shows for the first time that two doses of the COVID-19 vaccines are highly effective against the B.1.617.2 variant first identified in India. According to Public Health England (PHE), while the Pfizer/BioNTech vaccine was 88 per cent effective against symptomatic COVID-19 from the B1.617.2 variant of concern (VOC) two weeks after the second dose, the Oxford/AstraZeneca vaccine was 60 per cent effective against the symptomatic disease caused by the B1.617.2 VOC.

However, the effectiveness from both types of vaccines was found to be only 33 per cent against the VOC found in India after just one dose of either jab.

The analysis shows that vaccine effectiveness against symptomatic disease from the B.1.617.2 variant is similar after two doses compared to the B1.1.7 VOC discovered in Kent and currently the dominant variant in the UK.

The Pfizer jabs were found to be 93 per cent effective against the B1.1.7 VOC compared to 66 per cent effectiveness from AstraZeneca against the B.1.1.7 variant.

After just one dose, they both showed around 50 per cent effectiveness against the B1.1.7 VOC. PHE said it expects to see even higher levels of effectiveness against hospitalisation and death over time.

This study provides reassurance that two doses of either vaccine offer high levels of protection against symptomatic disease from the B1.617.2 variant, said Dr Mary Ramsay, Head of Immunisation at PHE.

Also Read: First Case Of Patient Infected With Black, White And Yellow Fungus Reported From UP’s Ghaziabad

We expect the vaccines to be even more effective at preventing hospitalisation and death, so it is vital to get both doses to gain maximum protection against all existing and emerging variants, she said.

The analysis included data for all age groups from April 5 to cover the period since the B1.617.2 VOC emerged. It included 1,054 people confirmed as having the B1.617.2 variant through genomic sequencing, including participants of several ethnicities.

PHE noted that the difference in effectiveness between the vaccines after two doses may be explained by the fact that rollout of second doses of AstraZeneca was later than for the Pfizer vaccine, and other data on antibody profiles show it takes longer to reach maximum effectiveness with the AstraZeneca vaccine.

Separate PHE analysis indicates that the COVID-19 vaccination programme has so far prevented 13,000 deaths and around 39,100 hospitalisations in older people in England, up to May 9.

Dr Rajeev Jayadevan, Deputy Medical Director at Sunrise Group of Hospitals in Kochi says that variants are normal expected evolutionary outcomes from virus. He also spoke about how we have on ground evidence of vaccine’s efficiency against the COVID-19. He tells NDTV,

What we see in India, people who are vaccinated are not getting hospitalised. Hospitals in India maybe full, but there is no one who has received two doses of vaccine. That is hard and on the ground evidence that the vaccines work.

Also Read: Women Can Get COVID Vaccine Anytime After Delivery: Experts

Dr Jayadevan further says that we have a very good data coming from PHE who have done a fantastic job on keeping the rest of the world updated on what is happening in England.

Genome sequencing in England is one of the best in the world, and they have actively sequenced all the cases that are coming into their country. Therefore, as part of their evaluation, we have almost 3,000 patients that they have identified with this new variant – B.1.617.2. What is encouraging is that only 1 per cent of these people, need hospitalisation. So, that is the same as the original virus. 3,000 is not a small number, but it is not a very big number either. The other aspect is the vaccines. UK has used AstraZeneca or the British version of Covidsheild, and Pfizer, so those who take both doses are at least 80 per cent protected from symptomatic disease, he said.

Dr Jayadevan also explained two expected outcomes and types of protection with any vaccine. He said,

Most people know that in vaccination we talk about two types of protection- symptomatic disease protection. But what healthcare workers and experts are most concerned about is hospitalisation or serious illness protection. When it comes to critical illness protection or severe infection, all of the 10-12 vaccines that are licensed to use around the world, are excellent at preventing severe disease. Of course there may be some exceptions.

While there is an ongoing debate over if the second wave of infection is affecting more younger people. This study also found that the variant found in India not causing severe diseases. Dr Jayadevan explains,

There are a couple of entities in the second wave, the first is how many people are getting infected and second is how many people are dying, if a 100 people are infected. Both are separate numbers. So, the first if we unleash this variant into a new village, how many will get infection. It is estimated in the world through various modelling studies that the B.1.617.2 variant is significantly more transmissible than the variant which we had in our country last year, and also the variant that first originated in UK. There’s no doubt about that. What is difficult is to separate the behaviour of the virus and the behaviour of human beings. The casual attitude of the people who believe that the virus has gone away and they have not been taking precautions has caused a lot. Secondly, the most important is how many people are dying. If, for experimental sake, we infect 100 people from the new virus strain, and the same number of people from the old strain, the same number of deaths, severe disease will occur and the same number will end up in ICUs. That is the most important message here.

Also Read: A Survivor’s Story: Hyderabad’s Youngest COVID Patient Defeats Coronavirus Successfully

PHE has said there are currently insufficient cases and follow-up periods to estimate vaccine effectiveness against severe outcomes from the B1.617.2 variant but added that it will continue to evaluate this over the coming weeks. However, as with other variants, it remains confident that even higher levels of effectiveness are expected against hospitalisation and death.

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

World

17,66,30,634Cases
5,80,25,717Active
11,47,82,895Recovered
38,22,022Deaths
Coronavirus has spread to 193 countries. The total confirmed cases worldwide are 17,66,30,634 and 38,22,022 have died; 5,80,25,717 are active cases and 11,47,82,895 have recovered as on June 16, 2021 at 3:30 am.

India

2,96,33,105 62,224Cases
8,65,43247,946Active
2,83,88,100 1,07,628Recovered
3,79,573 2,542Deaths
In India, there are 2,96,33,105 confirmed cases including 3,79,573 deaths. The number of active cases is 8,65,432 and 2,83,88,100 have recovered as on June 16, 2021 at 2:30 am.

State Details

State Cases Active Recovered Deaths
Maharashtra

59,24,773 7,652

1,41,440 8,982

56,69,179 15,176

1,14,154 1,458

Karnataka

27,77,010 5,041

1,62,303 9,859

25,81,559 14,785

33,148 115

Kerala

27,48,204 12,246

1,12,792 1,456

26,23,904 13,536

11,508 166

Tamil Nadu

23,78,298 11,805

1,25,215 11,669

22,23,015 23,207

30,068 267

Andhra Pradesh

18,20,134 5,741

75,134 4,879

17,32,948 10,567

12,052 53

Uttar Pradesh

17,03,207 270

7,221 890

16,74,072 1,104

21,914 56

West Bengal

14,68,044 3,268

20,046 1,125

14,30,949 2,068

17,049 75

Delhi

14,31,498 228

3,078 148

14,03,569 364

24,851 12

Chhattisgarh

9,88,172 609

11,717 943

9,63,113 1,544

13,342 8

Rajasthan

9,50,133 172

5,619 848

9,35,658 1,006

8,856 14

Odisha

8,59,526 3,405

44,358 3,436

8,11,780 6,799

3,388 42

Gujarat

8,21,078 352

8,884 658

8,02,187 1,006

10,007 4

Madhya Pradesh

7,88,649 224

3,610 331

7,76,424 528

8,615 27

Haryana

7,66,357 228

3,703 374

7,53,584 564

9,070 38

Bihar

7,17,949 410

4,360 412

7,04,075 813

9,514 9

Telangana

6,06,436 1,556

19,933 528

5,82,993 2,070

3,510 14

Punjab

5,89,153 628

10,802 1,111

5,62,701 1,691

15,650 48

Assam

4,66,590 3,415

41,184 475

4,21,378 2,906

4,028 34

Jharkhand

3,43,793 184

2,646 416

3,36,058 596

5,089 4

Uttarakhand

3,37,449 274

3,642 266

3,26,822 515

6,985 25

Jammu And Kashmir

3,08,726 715

12,407 1,125

2,92,114 1,830

4,205 10

Himachal Pradesh

1,99,197 321

4,050 382

1,91,737 691

3,410 12

Goa

1,63,048 327

4,175 231

1,55,926 548

2,947 10

Puducherry

1,13,192 355

4,668 279

1,06,828 629

1,696 5

Chandigarh

61,200 40

486 21

59,917 58

797 3

Manipur

61,096 785

8,744 301

51,354 476

998 8

Tripura

60,385 536

4,886 65

54,870 596

629 5

Meghalaya

42,759 450

4,430 99

37,579 542

750 7

Arunachal Pradesh

31,938 290

2,849 40

28,934 326

155 4

Nagaland

23,854 101

2,972 229

20,423 327

459 3

Ladakh

19,649 38

552 20

18,898 57

199 1

Sikkim

18,659 209

3,239 67

15,136 273

284 3

Mizoram

15,899 268

3,637 45

12,191 312

71 1

Dadra And Nagar Haveli

10,473 9

61 2

10,408 7

4

Lakshadweep

9,297 61

484 36

8,768 96

45 1

Andaman And Nicobar Islands

7,280 11

105 4

7,049 15

126

Coronavirus Outbreak: Full CoverageTesting CentresFAQs

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like

Gurugram Tops In Anti-Covid Vaccination Coverage, Reveals A Union Government’s Survey

Till June 12, over 8.5 lakh people in Gurgaon have been vaccinated against the COVID-19 with both doses of the vaccine, said Haryana Health Minister Anil Vij